Search Results - "Arends, Rosalinda H"

Harnessing Clinical Trial and Real-World Data Towards an Understanding of Sex Effects on Drug Pharmacokinetics, Pharmacodynamics and Efficacy by Oi Yan Chan, Joyce, Moullet, Marie, Williamson, Beth, Arends, Rosalinda H., Pilla Reddy, Venkatesh

“…Increasing clinical data on sex-related differences in drug efficacy and toxicity has highlighted the importance of understanding the impact of sex on drug…”
Get full text

Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction by Gill, Jaidip, Moullet, Marie, Martinsson, Anton, Miljković, Filip, Williamson, Beth, Arends, Rosalinda H., Pilla Reddy, Venkatesh

“…The gold‐standard approach for modeling pharmacokinetic mediated drug–drug interactions is the use of physiologically‐based pharmacokinetic modeling and…”
Get full text

Evaluating the performance of machine‐learning regression models for pharmacokinetic drug–drug interactions by Gill, Jaidip, Moullet, Marie, Martinsson, Anton, Miljković, Filip, Williamson, Beth, Arends, Rosalinda H., Pilla Reddy, Venkatesh

“…Combination therapy or concomitant drug administration can be associated with pharmacokinetic drug–drug interactions, increasing the risk of adverse drug…”
Get full text

Development of and insights from systems pharmacology models of antibody‐drug conjugates by Lam, Inez, Pilla Reddy, Venkatesh, Ball, Kathryn, Arends, Rosalinda H., Mac Gabhann, Feilim

“…Antibody‐drug conjugates (ADCs) have gained traction in the oncology space in the past few decades, with significant progress being made in recent years…”
Get full text

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 by Levin, Myron J., Ustianowski, Andrew, De Wit, Stéphane, Launay, Odile, Avila, Miles, Templeton, Alison, Yuan, Yuan, Seegobin, Seth, Ellery, Adam, Levinson, Dennis J., Ambery, Philip, Arends, Rosalinda H., Beavon, Rohini, Dey, Kanika, Garbes, Pedro, Kelly, Elizabeth J., Koh, Gavin C.K.W., Near, Karen A., Padilla, Kelly W., Psachoulia, Konstantina, Sharbaugh, Audrey, Streicher, Katie, Pangalos, Menelas N., Esser, Mark T.

“…This randomized, controlled trial evaluated AZD7442 (a combination of tixagevimab and cilgavimab, monoclonal antibodies targeting the SARS-CoV-2 spike protein)…”
Get full text

Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes by Guan, Ye, Ly, Neang, Li, Jing, Arends, Rosalinda H.

“…Background and Objectives Cotadutide is a balanced dual glucagon-like peptide-1/glucagon receptor agonist under development for the treatment of nonalcoholic…”
Get full text

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans by Loo, Yueh-Ming, McTamney, Patrick M, Arends, Rosalinda H, Abram, Michael E, Aksyuk, Anastasia A, Diallo, Seme, Flores, Daniel J, Kelly, Elizabeth J, Ren, Kuishu, Roque, Richard, Rosenthal, Kim, Streicher, Katie, Tuffy, Kevin M, Bond, Nicholas J, Cornwell, Owen, Bouquet, Jerome, Cheng, Lily I, Dunyak, James, Huang, Yue, Rosenbaum, Anton I, Pilla Reddy, Venkatesh, Andersen, Hanne, Carnahan, Robert H, Crowe, Jr, James E, Kuehne, Ana I, Herbert, Andrew S, Dye, John M, Bright, Helen, Kallewaard, Nicole L, Pangalos, Menelas N, Esser, Mark T

“…Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there remains a need for more prevention and treatment options…”
Get more information

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019 by Levin, Myron J, Ustianowski, Andrew, Thomas, Steven, Templeton, Alison, Yuan, Yuan, Seegobin, Seth, Houlihan, Catherine F, Menendez-Perez, Ibrahim, Pollett, Simon, Arends, Rosalinda H, Beavon, Rohini, Dey, Kanika, Garbes, Pedro, Kelly, Elizabeth J, Koh, Gavin C K W, Ivanov, Stefan, Near, Karen A, Sharbaugh, Audrey, Streicher, Katie, Pangalos, Menelas N, Esser, Mark T

“…Abstract Background This phase 3 trial assessed AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis against symptomatic coronavirus disease 2019…”
Get full text

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults by Forte-Soto, Pablo, Albayaty, Muna, Brooks, Dennis, Arends, Rosalinda H, Tillinghast, John, Aksyuk, Anastasia A, Bouquet, Jerome, Chen, Cecil, Gebre, Asfiha, Kubiak, Robert J, Pilla Reddy, Venkatesh, Seegobin, Seth, Streicher, Katie, Templeton, Alison, Esser, Mark T

“…Abstract Background AZD7442 is a combination of extended half-life, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)−specific neutralizing…”
Get full text

Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination by Mu, Ruipeng, Huang, Yue, Bouquet, Jerome, Yuan, Jiaqi, Kubiak, Robert J., Ma, Eric, Naser, Sami, Mylott, William R., Ismaiel, Omnia A., Wheeler, Aaron M., Burkart, Rebecca, Cortes, Diego F., Bruton, James, Arends, Rosalinda H., Liang, Meina, Rosenbaum, Anton I.

“…AZD7442 (tixagevimab [AZD8895]/cilgavimab [AZD1061]) is a monoclonal antibody (mAb) combination in development for the prevention and treatment of coronavirus…”
Get full text

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 by Levin, Myron J., Ustianowski, Andrew, De Wit, Stéphane, Launay, Odile, Avila, Miles, Templeton, Alison, Yuan, Yuan, Seegobin, Seth, Ellery, Adam, Levinson, Dennis J., Ambery, Philip, Arends, Rosalinda H., Beavon, Rohini, Dey, Kanika, Garbes, Pedro, Kelly, Elizabeth J., Koh, Gavin C.K.W., Near, Karen A., Padilla, Kelly W., Psachoulia, Konstantina, Sharbaugh, Audrey, Streicher, Katie, Pangalos, Menelas N., Esser, Mark T.

Get full text

Confirmatory cut point has limited ability to make accurate classifications in immunogenicity assays by Kubiak, Robert J, Arends, Rosalinda H G P, Lee, Nancy, Liang, Meina, Zhang, Jianchun, Roskos, Lorin K

“…Competitive inhibition with excess unlabeled drug is used to confirm the presence of antidrug antibodies (ADA) in study samples. We evaluated specific and…”
Get full text

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults by Levin, Myron J, Ustianowski, Andrew, De Wit, Stéphane, Launay, Odile, Avila, Miles, Seegobin, Seth, Templeton, Alison, Yuan, Yuan, Ambery, Philip, Arends, Rosalinda H, Beavon, Rohini, Near, Karen A, Padilla, Kelly W, Psachoulia, Konstantina, Sharbaugh, Audrey, Streicher, Katie, Pangalos, Menelas N, Esser, Mark T, Gasser, Robert A

Get full text